Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 07, 2022 07:00 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022

SEATTLE and CAMBRIDGE, United Kingdom, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
January 18, 2022 07:00 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones

ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled Investigational New Drug (IND) application planned in Q1 2022 for ETX-155 Phase 2 trials in major depressive...
November 08, 2021 16:01 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress made toward the initiation of major depressive...
November 04, 2021 07:00 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics to Participate at Four Upcoming Investor Conferences

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal...
September 13, 2021 16:10 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics Reports Second Quarter Financial Results

On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross...
August 12, 2021 21:06 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

SEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
August 09, 2021 22:33 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics Announces Pricing of Initial Public Offering

SEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal...